LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos

被引:130
作者
Badimon, Lina [1 ,2 ,3 ]
Vilahur, Gemma [1 ,2 ]
机构
[1] IIB St Pau, Hosp Santa Creu & St Pau, CSIC ICCC, Cardiovasc Res Ctr, Barcelona 08025, Spain
[2] CIBEROBN Pathophysiol Obes & Nutr, Barcelona, Spain
[3] Univ Autonoma Barcelona, Cardiovasc Res Chair, E-08193 Barcelona, Spain
来源
EVOLVING CHALLENGES IN PROMOTING CARDIOVASCULAR HEALTH | 2012年 / 1254卷
关键词
high-density lipoproteins; low-density lipoproteins; atherothrombosis; HIGH-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; RECEPTOR-RELATED PROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; FACTOR PATHWAY INHIBITOR; EMERGING RISK-FACTORS; AGGREGATED LDL; MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION;
D O I
10.1111/j.1749-6632.2012.06480.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is a complex disease in which many processes contribute to lesion development. Yet, it is well accepted that high serum levels of low-density lipoproteins (LDL) play a main role in the initiation and progression of atherosclerosis. Despite currently available optimal LDL-lowering therapies, a worrisome number of clinical events still occur. The protective effect of high-density lipoproteins (HDL) in atherosclerosis, either by suppressing vascular LDL accumulation, inflammation, oxidation, endothelial damage, and thrombosis, has supported the need of the use of HDL-raising therapies to address this residual risk. Results obtained in some studies, however, have shown that HDL quality, rather than quantity, should be the target of future pharmacological therapies. Here, we will first explore the mechanism by which excess LDL is fundamental in the development of atherosclerosis and its thrombotic complications, behaving as a factor that introduces chaos in the vascular wall. Afterwards, we will explore how functional HDL, through various cellular and molecular mechanisms, facilitates the resolution of this vascular chaos by suppression of atherosclerosis progression and induction of regression.
引用
收藏
页码:18 / 32
页数:15
相关论文
共 102 条
[1]  
[Anonymous], 1984, JAMA, V252, P2545
[2]  
[Anonymous], 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138
[3]   Implications emerging risk factors for therapeutic intervention [J].
Assmann, G ;
Cullen, P ;
Fruchart, JC ;
Greten, H ;
Naruszewicz, M ;
Olsson, A ;
Paoletti, R ;
Riesen, W ;
Stoll, M ;
Tikkanen, M ;
von Eckardstein, A .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2005, 15 (05) :373-381
[4]   HDL cholesterol and protective factors in atherosclerosis [J].
Assmann, G ;
Gotto, AM .
CIRCULATION, 2004, 109 (23) :8-14
[5]   High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A ;
Huang, YD .
ATHEROSCLEROSIS, 1996, 124 :S11-S20
[6]   Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities [J].
Aviram, M ;
Hardak, E ;
Vaya, J ;
Mahmood, S ;
Milo, S ;
Hoffman, A ;
Billicke, S ;
Draganov, D ;
Rosenblat, M .
CIRCULATION, 2000, 101 (21) :2510-2517
[7]   PLASMA-LIPOPROTEINS AFFECT PLATELET MALONDIALDEHYDE AND THROMBOXANE B-2 PRODUCTION [J].
AVIRAM, M ;
SIRTORI, CR ;
COLLI, S ;
MADERNA, P ;
MORAZZONI, G ;
TREMOLI, E .
BIOCHEMICAL MEDICINE, 1985, 34 (01) :29-36
[8]  
Badimon J.J., REV ESP CARDIOL S2, V63, P20
[9]  
BADIMON JJ, 1989, LAB INVEST, V60, P455
[10]   Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions [J].
Badimon, JJ ;
Lettino, M ;
Toschi, V ;
Fuster, V ;
Berrozpe, M ;
Chesebro, JH ;
Badimon, L .
CIRCULATION, 1999, 99 (14) :1780-1787